Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further ...

A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to ...

to $1.42 near the close of trading after the Food and Drug Administration announced that it is replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...

The proportion of responders was 39.1% among patients with single-class refractory disease and 33.7% among patients with penta-class refractory disease. Patients with relapsed or refractory ...

“With Anti-Semitism dangerously on the rise, Yehuda will be the strongest Representative for Americans and Jews across the Globe, and promote PEACE. Congratulations Yehuda!” Trump’s ...